Erratum: A Cationic-Independent Mannose 6-Phosphate Receptor Inhibitor (PXS64) Ameliorates Kidney Fibrosis by Inhibiting Activation of Transforming Growth Factor-β1 (PLoS ONE (2015) 10:2 (e0116888) DOI: 10.1371/journal.pone.0116888);A cationic-independent mannose 6-phosphate receptor inhibitor (PXS64) ameliorates kidney fibrosis by inhibiting activation of transforming growth factor-β1

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Zhang, Jie ^a   Wong, Muh Geot ^a   Wong, May ^a   Gross, Simon ^a   Chen, Jason ^b   Pollock, Carol ^a   Saad, Sonia ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; CD45 ANTIGEN; CD68 ANTIGEN; COLLAGEN TYPE 4; FIBRONECTIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PXS 64; SMAD2 PROTEIN; SOMATOMEDIN B RECEPTOR; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; MANNOSIDE; PHOSPHONIC ACID DERIVATIVE; PRODRUG; PXS64 COMPOUND; SMAD2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MACROPHAGE MIGRATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; SIGNAL TRANSDUCTION; URETER OBSTRUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; KIDNEY TUBULE; METABOLISM; NEUTROPHIL; PATHOLOGY;

ANIMALIA; MUS;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; KIDNEY TUBULES; MALE; MANNOSIDES; MICE, INBRED C57BL; NEUTROPHILS; ORGANOPHOSPHONATES; PRODRUGS; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; URETERAL OBSTRUCTION;

EID: 84922757735     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0262725     Document Type: Erratum

References (37)

1. White KE, Bilous RW (2000) Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 11: 1667-1673. PMID: 10966491
2. Ruiz-Torres MP, Lopez-Ongil S, Griera M, Diez-Marques ML, Rodriguez-Puyol M, et al. (2005) The accumulation of extracellular matrix in the kidney: consequences on cellular function. J Nephrol 18: 334-340. PMID: 16013026
3. Berl T (2009) Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 10: 1-8. doi: 10.1177/1470320309102747 PMID: 19286752
4. Dennler S, Goumans MJ, ten Dijke P (2002) Transforming growth factor beta signal transduction. J Leukoc Biol 71: 731-740. PMID: 11994497
5. Meng XM, Huang XR, Xiao J, Chung AC, Qin W, et al. (2012) Disruption of Smad4 impairs TGF-beta/ Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int 81: 266-279. doi: 10.1038/ki.2011.327 PMID: 22048127
6. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, et al. (2004) Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 18: 176-178. PMID: 12709399
7. Bottinger EP, Bitzer M (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13: 2600-2610. doi: 10.1097/01.ASN.0000033611.79556.AE PMID: 12239251
8. Hayashida T, Decaestecker M, Schnaper HW (2003) Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J 17: 1576-1578. PMID: 12824291
9. Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RK, et al. (2009) TGF-beta signal transduction in chronic kidney disease. Front Biosci (Landmark Ed) 14: 2448-2465. doi: 10.2741/3389
10. Gewin L, Zent R (2012) How does TGF-beta mediate tubulointerstitial fibrosis? Semin Nephrol 32: 228-235. doi: 10.1016/j.semnephrol.2012.04.001 PMID: 22835453
11. Lyons RM, Keski-Oja J, Moses HL (1988) Proteolytic activation of latent transforming growth factorbeta from fibroblast-conditioned medium. J Cell Biol 106: 1659-1665. doi: 10.1083/jcb.106.5.1659 PMID: 2967299
12. Rogers ML, Goddard C, Regester GO, Ballard FJ, Belford DA (1996) Transforming growth factor beta in bovine milk: concentration, stability and molecular mass forms. J Endocrinol 151: 77-86. doi: 10. 1677/joe.0.1510077 PMID: 8943771
13. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176. PMID: 10652271
14. Barcellos-Hoff MH, Dix TA (1996) Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10: 1077-1083. doi: 10.1210/mend.10.9.8885242 PMID: 8885242
15. Godar S, Horejsi V, Weidle UH, Binder BR, Hansmann C, et al. (1999) M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur J Immunol 29: 1004-1013. doi: 10.1002/(SICI)1521-4141(199903)29:03%3C1004::AID-IMMU1004%3E3.0. CO;2-Q PMID: 10092105
16. Jones-Carson J, Fantuzzi G, Siegmund B, Dinarello C, Tracey KJ, et al. (2005) Suppressor alphabeta T lymphocytes control innate resistance to endotoxic shock. J Infect Dis 192: 1039-1046. doi: 10. 1086/432727 PMID: 16107957
17. Czupalla C, Mansukoski H, Riedl T, Thiel D, Krause E, et al. (2006) Proteomic analysis of lysosomal acid hydrolases secreted by osteoclasts: implications for lytic enzyme transport and bone metabolism. Mol Cell Proteomics 5: 134-143. doi: 10.1074/mcp.M500291-MCP200 PMID: 16215273
18. Bates SJ, Morrow E, Zhang AY, Pham H, Longaker MT, et al. (2006) Mannose-6-phosphate, an inhibitor of transforming growth factor-beta, improves range of motion after flexor tendon repair. J Bone Joint Surg Am 88: 2465-2472. doi: 10.2106/JBJS.E.00143 PMID: 17079405
19. Black DA, Tucci M, Puckett A, Benghuzzi H (2012) Histopathological and biomechanical parameters of repaired rat achilles tendons treated with and without mannose-6-phosphate. Biomed Sci Instrum 48: 43-48. PMID: 22846263
20. Ngeow WC, Atkins S, Morgan CR, Metcalfe AD, Boissonade FM, et al. (2011) The effect of Mannose- 6-Phosphate on recovery after sciatic nerve repair. Brain Res 1394: 40-48. doi: 10.1016/j.brainres. 2011.04.021 PMID: 21550591
21. Willenborg DO, Parish CR, Cowden WB (1989) Phosphosugars are potent inhibitors of central nervous system inflammation. FASEB J 3: 1968-1971. PMID: 2721857
22. Wong MG, Panchapakesan U, Qi W, Silva DG, Chen XM, et al. (2011) Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol 301: F84-93. doi: 10.1152/ ajprenal.00287.2010 PMID: 21478477
23. Klahr S, Morrissey J (2002) Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283: F861-875. PMID: 12372761
24. Vaughan ED Jr, Marion D, Poppas DP, Felsen D (2004) Pathophysiology of unilateral ureteral obstruction: studies from Charlottesville to New York. J Urol 172: 2563-2569. doi: 10.1097/01.ju.0000144286. 53562.95 PMID: 15538209
25. Stegemann H, Stalder K (1967) Determination of hydroxyproline. Clin Chim Acta 18: 267-273. doi: 10. 1016/0009-8981(67)90167-2 PMID: 4864804
26. Bohle A, Christ H, Grund KE, Mackensen S (1979) The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol 16: 109-114. PMID: 467060
27. Strutz F, Muller GA (1999) Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press Res 22: 71-80. doi: 10.1159/000025911 PMID: 10352410
28. Harris WT, Kelly DR, Zhou Y, Wang D, Macewen M, et al. (2013) Myofibroblast differentiation and enhanced TGF-B signaling in cystic fibrosis lung disease. PLoS One 8: e70196. doi: 10.1371/journal. pone.0070196 PMID: 23950911
29. Eddy AA (2000) Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301. doi: 10.1007/ s004670000461 PMID: 11149129
30. Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471. doi: 10.1038/37284 PMID: 9393997
31. Li Y, Sun Y, Liu F, Sun L, Li J, et al. (2013) Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition. PLoS One 8: e66356. doi: 10.1371/journal.pone. 0066356 PMID: 23825538
32. Pan MM, Zhang MH, Ni HF, Chen JF, Xu M, et al. (2013) Inhibition of TGF-beta1/Smad signal pathway is involved in the effect of Cordyceps sinensis against renal fibrosis in 5/6 nephrectomy rats. Food Chem Toxicol 58: 487-494. doi: 10.1016/j.fct.2013.04.037 PMID: 23624380
33. Hsieh PF, Liu SF, Lee TC, Huang JS, Yin LT, et al. (2012) The role of IL-7 in renal proximal tubule epithelial cells fibrosis. Mol Immunol 50: 74-82. doi: 10.1016/j.molimm.2011.12.004 PMID: 22261356
34. Sakairi T, Hiromura K, Takahashi S, Hamatani H, Takeuchi S, et al. (2011) Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo. Nephrology (Carlton) 16: 76-86. doi: 10.1111/j.1440-1797. 2010.01367.x
35. Djamali A, Vidyasagar A, Yagci G, Huang LJ, Reese S (2010) Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. Transplantation 90: 387-393. doi: 10.1097/TP.0b013e3181e6ae0a PMID: 20548261
36. Eddy AA, Neilson EG (2006) Chronic kidney disease progression. J Am Soc Nephrol 17: 2964-2966. doi: 10.1681/ASN.2006070704 PMID: 17035605
37. Mimura I, Nangaku M (2010) The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 6: 667-678.